Education
About Us
Working with TipRanks
Follow Us
Brainstorm Cell Therapeutics (BCLI)
NASDAQ:BCLI
RESEARCH TOOLSreports
Total Valuation
Brainstorm Cell Therapeutics has a market cap or net worth of $7.27M. The enterprise value is $14.77M.
Market Cap$7.27M
Enterprise Value$14.77M
Share Statistics
Brainstorm Cell Therapeutics has 6.52M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6.52M
Owened by Insiders20.15%
Owened by Instutions2.66%
Financial Efficiency
Brainstorm Cell Therapeutics’s return on equity (ROE) is 3.54 and return on invested capital (ROIC) is 596.85%.
Return on Equity (ROE)353.89%
Return on Assets (ROA)-408.56%
Return on Invested Capital (ROIC)596.85%
Return on Capital Employed (ROCE)596.85%
Revenue Per Employee$4,793.103
Profits Per Employee-$490,620.69
Employee Count29
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Brainstorm Cell Therapeutics is -10.25. Brainstorm Cell Therapeutics’s PEG ratio is 0.27.
PE Ratio-10.25
PS Ratio0.00
PB Ratio-36.27
Price to Fair Value-36.27
Price to FCF-8.61K
Price to Operating Cash Flow-8.61
PEG Ratio0.27
Income Statement
In the last 12 months, Brainstorm Cell Therapeutics had revenue of $139.00K and earned -$14.23M in profits. Earnings per share was -$1.21.
Revenue$139.00K
Gross Profit-$55.00K
Operating Income-$13.31M
Pretax Income-$14.23M
Net Income-$14.23M
EBITDA-13.39M
Earnings Per Share (EPS)-1.21
Cash Flow
In the last 12 months, operating cash flow was -$11.33M and capital expenditures $1.68M, giving a free cash flow of -$11.33M billion.
Operating Cash Flow-$11.33M
Free Cash Flow-$11.33M
Free Cash Flow per Share-$1.74
Dividends & Yields
Brainstorm Cell Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-0.01%
Earnings Yield-9.76%
Stock Price Statistics
Beta1.95
52-Week Price Change-91.32%
50-Day Moving Average1.52
200-Day Moving Average2.76
Relative Strength Index (RSI)28.78
Average Volume (3m)34.24K
Important Dates
Brainstorm Cell Therapeutics upcoming earnings date is May 19, 2025, TBA.
Last Earnings DateMar 31, 2025
Next Earnings DateMay 19, 2025
Ex-Dividend Date―
Financial Position
Brainstorm Cell Therapeutics as a current ratio of 0.24, with Debt / Equity ratio of -0.14
Current Ratio0.24
Quick Ratio0.24
Debt to Market Cap0.00
Net Debt to EBITDA0.04
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Brainstorm Cell Therapeutics has paid $4.99M in taxes.
Income Tax$4.99M
Effective Tax Rate0.00%
Enterprise Valuation
Brainstorm Cell Therapeutics EV to EBITDA ratio is -10.37, with an EV/FCF ratio of -8.58K.
EV to Sales0.00
EV to EBITDA-10.37
EV to Free Cash Flow-8.58K
EV to Operating Cash Flow-8.58
Balance Sheet
Brainstorm Cell Therapeutics has $168.00K in cash and marketable securities with $841.00K in debt, giving a net cash position of $673.00K billion.
Cash & Marketable Securities$168.00K
Total Debt$841.00K
Net Cash$673.00K
Net Cash Per Share$0.10
Tangible Book Value Per Share-$0.11
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Brainstorm Cell Therapeutics is $6.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$6.00
Price Target Upside689.47%
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast
EPS Growth Forecast62.35%